In the ongoing battle against Type 2 diabetes, a condition where the body struggles with insulin’s effects or doesn’t produce enough insulin to maintain a healthy glucose level, a breakthrough has emerged.
While metformin has long been the cornerstone treatment to help stabilize blood glucose, its efficacy can diminish over time, leaving patients in search of additional therapies to manage their condition effectively.
Enter the promising combination of dapagliflozin and exenatide.
Researchers from Thomas Jefferson University have conducted a study that shines a hopeful light on this drug duo, revealing their sustained effectiveness in controlling blood glucose levels for over two years.
This finding is particularly significant for the 695 adults with Type 2 diabetes who participated in the study.
These individuals, whose diabetes was not adequately managed with metformin alone, were divided into three groups to explore the impact of combining therapies.
One group continued with metformin and added weekly injections of exenatide, another combined metformin with daily dapagliflozin pills, while the third group received a combination of both dapagliflozin and exenatide alongside metformin.
The results were clear: those on the dual drug regimen showed superior glycemic control compared to those on a single drug, a benefit that did not wane throughout the two-year study period.
Dapagliflozin belongs to a class of medications known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which help the body eliminate excess glucose through urine.
Exenatide, on the other hand, is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that boosts glucose-dependent insulin secretion, decreases glucose production in the liver, slows down the emptying of the stomach, and increases the feeling of fullness.
Together, these mechanisms not only enhance glucose control but also support weight loss and blood pressure improvement — two crucial aspects in managing Type 2 diabetes.
The study, under the leadership of Serge Jabbour and published in the journal Diabetes Care, not only underscores the long-term viability of combining dapagliflozin and exenatide but also highlights the absence of unexpected safety issues, adding a layer of reassurance for patients and healthcare providers alike.
This combination therapy offers a beacon of hope for those whose diabetes remains uncontrolled by metformin alone, presenting a robust strategy to manage their condition effectively.
The long-term success of this treatment approach could potentially reshape the management of Type 2 diabetes, offering patients a sustained solution to controlling their blood sugar levels while also addressing related health concerns such as weight and blood pressure.
If you care about diabetes, please read studies about Vitamin D and type 2 diabetes, and to people with diabetes, some fruits are better than others.
For more information about diabetes, please see recent studies that low calorie diets may help reverse diabetes, and 5 vitamins that may prevent complication in diabetes.
Copyright © 2024 Knowridge Science Report. All rights reserved.
